

<b>Society for Immunotherapy of Cancer (SITC) Session at SSO 2024</b> Saturday, March 23   12:30 pm -2:30 pm <i>Box lunches provided</i>	
12:30 p.m.	Welcome/Introduction
12:40 p.m.	<b>Neoadjuvant immune checkpoint inhibitors for resectable cancer at high risk of recurrence</b> Stephanie Downs-Canner, MD – <i>MSKCC</i>
1:05 p.m.	<b>Personalized vaccines in the adjuvant setting</b> Mark B. Faries, MD - <i>The Angeles Clinic and Research Institute</i>
1:30 p.m.	<b>T cell therapies for metastatic solid cancer</b> Simon Turcotte, MD, MSc, FRCSC – <i>Université de Montréal</i>
1:55 p.m.	<b>Clinical Case Discussions: Case studies on neoadjuvant immunotherapy</b> Moderator: Genevieve Boland, MD, PhD - <i>Massachusetts General Hospital</i>
2:25 p.m.	Closing Remarks